Related Experiment Video
Updated: May 22, 2025

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
SI/II Pocket of Ras: An Opportunity for a Once "Undruggable" Target
Tanos C C França1,2,3, Michael Maddalena4,5, Imène Kouidmi4,5
1INRS Centre Armand Frappier Santé Biotechnologie, 531 des Prairies Boulevard, Laval, Quebec H7 V 1B7, Canada.
Abstract:
Mutations on the Ras-family of small GTPases are among the most common molecular oncogenic drivers, with the HRas isoform being primarily associated with head-and-neck and genito-urinary cancers. Although once considered "undruggable," recent efforts have identified a structurally conserved surface pocket in the Ras family, designated the SI/II pocket, situated near the binding site of the guanidine exchange factor (GEF) SOS1. The SI/II pocket may represent a potential target site for a pan-Ras drug. A crystal structure representing the native state of GDP-bound HRasG12V was generated to characterize the topology of the SI/II pocket. This native-state structure was employed, together with the published structure of GppNHp-bound HRasG12V in state 1 (PDB ID: 4EFM), as a base for further molecular dynamics simulations exploring the conformational dynamics of the SI/II pocket via four generated synthetic HRas model structures. Our results show that the SI/II pocket is natively inaccessible in GDP-bound HRas yet becomes accessible in state 1 GppNHp-bound HRas systems, an effect that seems to be more evident in the mutated enzyme. This points to the GTP-bound state as a most promising target for Ras inhibitors directed at the SI/II pocket. Occlusion of the SI/II pocket is dictated by the spatial position of the α2 α helix in relation to the protein core, with α2 residue Y71 acting as a "tyrosine toggle" capable of restricting the pocket access.
Insights
Ras mutations drive cancer, but the SI/II pocket offers a new therapeutic target. This pocket is accessible in the GTP-bound state, suggesting it’s a promising site for novel Ras inhibitors.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Ras GTPases are key oncogenic drivers, particularly HRas in head-and-neck and genitourinary cancers.
- The previously undruggable Ras family now presents a potential target: the conserved SI/II pocket near the SOS1 binding site.
Purpose of the Study:
- To characterize the SI/II pocket's topology in GDP-bound HRasG12V.
- To investigate the conformational dynamics of the SI/II pocket in different HRas states.
Main Methods:
- Generated a crystal structure of native GDP-bound HRasG12V.
- Utilized molecular dynamics simulations on native and synthetic HRas models.
- Analyzed structures of GDP-bound and GppNHp-bound HRasG12V.
Main Results:
- The SI/II pocket is inaccessible in native GDP-bound HRas.
- The pocket becomes accessible in the GppNHp-bound state, especially in mutated HRas.
- The α2 helix and residue Y71 control pocket accessibility via a 'tyrosine toggle' mechanism.
Conclusions:
- The GTP-bound state of HRas is the most promising target for SI/II pocket-directed Ras inhibitors.
- Understanding the SI/II pocket's dynamics is crucial for developing pan-Ras drugs.
Related Concept Videos
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drug Discovery: Overview
The Ras Gene
Ras is a...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Experimental RNAi

